Targeted treatment approaches and pathogenicity of antibody subclasses in MuSK-myasthenia gravis
<p>Muscle Specific Kinase myasthenia gravis (MuSK-MG) is an autoimmune disease that impairs neuromuscular transmission leading to muscle fatigability. No targeted medications are currently available, and non-specific immunotherapies are required. MuSK initiates a phosphorylation cascade regula...
Main Author: | Cao, M |
---|---|
Other Authors: | Beeson, D |
Format: | Thesis |
Language: | English |
Published: |
2021
|
Subjects: |
Similar Items
-
Clinical Characteristics of MuSK Antibody-positive Myasthenia Gravis in Taiwan
by: Yung-Chuan Huang, et al.
Published: (2008-07-01) -
Coexistence of anti-MuSK antibody-positive myasthenia gravis and rheumatoid arthritis
by: Amber Eker, et al.
Published: (2020-08-01) -
Progress in rituximab for anti⁃MuSK antibody-related myasthenia gravis
by: Ting LI, et al.
Published: (2020-01-01) -
MuSK Myasthenia Gravis—Potential Pathomechanisms and Treatment Directed against Specific Targets
by: Edyta Dziadkowiak, et al.
Published: (2024-03-01) -
Regional Features of MuSK Antibody-Positive Myasthenia Gravis in Northeast China
by: Zunwei Zhang, et al.
Published: (2020-10-01)